Buy Like Buffett

The Moat Index

AMNEAL PHARMACEUTICALS, INC.

AMRX · Healthcare · FY2025 filings · No moat ·

Doesn't clear the bar

32/ 100
No moat

The four filters

Pricing power37

Median gross margin 36.6% over 10y, variable.

Returns on capital12

Median ROIC 3.5%, above the 9% hurdle in 33% of years.

Balance-sheet safety40

Net debt/EBITDA 5.8x, no material interest expense disclosed.

Capital discipline44

Owner earnings trend unclear, share count n/a.

Margin of safety

Above valueOn sale
No price data
Owner earnings (normalized)
—
Est. intrinsic value / share
—
Recent price
$17.85
Discount to value
No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

11 years of fundamentals

The business, in plain English

AMNEAL PHARMACEUTICALS, INC. booked $3.0B of revenue in FY2025 in the Healthcare sector and kept 36.9% of it as gross profit — a solid-margin business by that measure. After every other cost, 2.4% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $1.0B (FY2016) to $3.0B (FY2025) — about 12.8% a year compounded over 9 years.

It earned 16.3% on invested capital in FY2025, with a median of 3.5% across 9 filed years. The Returns on Capital filter above scores it 12/100.

The balance sheet carried $2.6B of total debt in FY2025 against $2.0M of owner earnings — roughly 1289.8 years of owner earnings to retire it all. Balance-Sheet Safety scores it 40/100.

Put together: Capital Discipline is the strongest of the four filters (44/100) and Returns on Capital the weakest (12/100), which is how AMRX lands at 32/100 — a None moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2015–FY2025 · 11 fiscal years, normalized from AMRX’s SEC filings

RevenueSales, as filed$3.0B FY2025
$0$2B2015201920232025
Gross marginRevenue kept after cost of goods36.9% FY2025
0%25%50%2015201920232025
Return on invested capitalOperating profit on the capital employed16.3% FY2025
0%10%2015201920232025
Owner earningsCash an owner could take out$2.0M FY2025
−$500M$02015201920232025

Gaps in a line mean that item isn’t in AMRX’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

3 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale31.5 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — AMRX has read No moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#340 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #338COHU COHU INC31.6No moat
  2. #339GPRO GOPRO, INC.31.5No moat
  3. #341EMMA EMMAUS LIFE SCIENCES, INC.31.4No moat
  4. #342PRGO Perrigo Company plc31.3No moat

Compare AMRX with its nearest peers →All Healthcare companies on the Index →

Common questions about AMRX

Does AMNEAL PHARMACEUTICALS, INC. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores AMNEAL PHARMACEUTICALS, INC. (AMRX) 31.5 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 37, returns on capital 12, balance-sheet safety 40, capital discipline 44.
How has AMRX's Moat Score changed over time?
The record logs 3 readings since Jul 17, 2026; the latest reads 31.5 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.
Embed this score on your site

One iframe, no script. The badge shows AMRX’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/AMRX"
  width="340" height="150" style="border:0"
  title="AMRX Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell AMRX. See the disclaimer.

AMNEAL PHARMACEUTICALS, INC. (AMRX) Moat Score — The Moat Index · Buy Like Buffett